What the trial was testing
The RISE enrolled 544 patients with schizophrenia. The study was sponsored by Teva Branded Pharmaceutical Products R&D and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
It was a large trial designed to confirm whether the treatment works well enough for wider use. Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.
What the results showed
Time to relapse stretched 5x longer with the monthly injection.
The Lancet Psychiatry · 2023 · NCT03503318
These findings — that time to relapse on monthly long-acting risperidone vs. inactive injection — were published in the The Lancet Psychiatry and represent the headline result of the study.
Researchers tracked outcomes across 544 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with schizophrenia, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
Risperidone extended-release injection (Uzedy) was FDA-approved in 2023 and is available now. It is given as an under-the-skin injection by a healthcare provider every one or two months. Ask a psychiatrist about long-acting injectable options if pill adherence is a challenge.
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open schizophrenia trials
Uppsala Psychosis Cohort
A multimodal longitudinal study in early stage psychosis patients and individuals at high risk for psychosis. Healthy controls are included for baseline comparisons. The aim is to investigate disease mechanisms of psychotic disorders, specifically focusing on the synaptic pruning hypothesis.
Early Identification of Patients Presenting a First Psychotic Episode, Non Answering to First Line Support Strategies
Researchers propose in this project to evaluate predictive factors of non response. It is defined by the lack of symptomatic remission at month 3, for patients presenting a first episode of psychosis. It will be performed on objective markers taken from imagery techniques. The link between evolution of these markers and clinical measures will be studied.